公开(公告)号：US20230204421A1

公开(公告)日：2023-06-29

申请号：US18171438

申请日：2023-02-20

申请人： Lonza Ltd

发明人： Thaddaeus Webster ,  Brian Hadley ,  Carrie Mason ,  Colin Jaques ,  Seshu Tummala ,  Ruth Christine Rowland-Jones ,  Yonatan Levinson ,  Nicholas Uth ,  Pankaj Sinha ,  Eytan Abraham

IPC分类号： G01J3/44 ,  G01N21/65 ,  C12M1/36 ,  C12M1/34 ,  C12M1/00 ,  C12N5/0735 ,  C12N5/0783

CPC分类号： G01J3/44 ,  G01N21/65 ,  C12M41/48 ,  C12M41/36 ,  C12M31/08 ,  C12M41/32 ,  C12N5/0606 ,  C12N5/0636 ,  G01N2201/129 ,  G01N2021/8411

摘要： The monitoring and control of bioprocesses is provided. The present disclosure provides the ability to generate generic calibration models, independent of cell line, using inline Raman probes to monitor changes in glucose, lactate, glutamate, ammonium, viable cell concentration (VCC), total cell concentration (TCC) and product concentration. Calibration models were developed from cell culture using two different CHOK1SV GS-KO™ cell lines producing different monoclonal antibodies (mAbs). Developed predictive models, qualified using an independent CHOK1SV GS-KO™ cell line not used in calibration, measured changes in glucose, lactate, ammonium, VCC, and TCC with minor prediction errors over the course of cell culture with minimal cell line dependence. The development of these generic models allows the application of spectroscopic PAT techniques in a clinical manufacturing environment, where processes are typically run once or twice in GMP manufacturing based on a common platform process.

公开(公告)号：US11609120B2

公开(公告)日：2023-03-21

申请号：US16152950

申请日：2018-10-05

申请人： Lonza Ltd.

发明人： Thaddaeus Webster ,  Brian Hadley ,  Carrie Mason ,  Colin Jaques ,  Seshu Tummala ,  Ruth Christine Rowland-Jones ,  Yonatan Levinson ,  Nicholas Uth ,  Pankaj Sinha ,  Eytan Abraham

IPC分类号： G01J3/44 ,  G01N21/65 ,  C12M1/36 ,  C12M1/34 ,  C12M1/00 ,  C12N5/0735 ,  C12N5/0783 ,  G01N21/84

摘要： The monitoring and control of bioprocesses is provided. The present disclosure provides the ability to generate generic calibration models, independent of cell line, using inline Raman probes to monitor changes in glucose, lactate, glutamate, ammonium, viable cell concentration (VCC), total cell concentration (TCC) and product concentration. Calibration models were developed from cell culture using two different CHOK1SV GS-KO™ cell lines producing different monoclonal antibodies (mAbs). Developed predictive models, qualified using an independent CHOK1SV GS-KO™ cell line not used in calibration, measured changes in glucose, lactate, ammonium, VCC, and TCC with minor prediction errors over the course of cell culture with minimal cell line dependence. The development of these generic models allows the application of spectroscopic PAT techniques in a clinical manufacturing environment, where processes are typically run once or twice in GMP manufacturing based on a common platform process.

公开(公告)号：US20190137338A1

公开(公告)日：2019-05-09

申请号：US16152950

申请日：2018-10-05

申请人： Lonza Ltd.

发明人： Thaddaeus Webster ,  Brian Hadley ,  Carrie Mason ,  Colin Jaques ,  Seshu Tummala ,  Ruth Christine Rowland-Jones ,  Yonatan Levinson ,  Nicholas Uth ,  Pankaj Sinha ,  Eytan Abraham

IPC分类号： G01J3/44 ,  C12N5/0783 ,  G01N21/65 ,  C12N5/0735

摘要： The monitoring and control of bioprocesses is provided. The present disclosure provides the ability to generate generic calibration models, independent of cell line, using inline Raman probes to monitor changes in glucose, lactate, glutamate, ammonium, viable cell concentration (VCC), total cell concentration (TCC) and product concentration. Calibration models were developed from cell culture using two different CHOK1SV GS-KO™ cell lines producing different monoclonal antibodies (mAbs). Developed predictive models, qualified using an independent CHOK1SV GS-KO™ cell line not used in calibration, measured changes in glucose, lactate, ammonium, VCC, and TCC with minor prediction errors over the course of cell culture with minimal cell line dependence. The development of these generic models allows the application of spectroscopic PAT techniques in a clinical manufacturing environment, where processes are typically run once or twice in GMP manufacturing based on a common platform process.